Pósa, V.; Stefanelli, A.; Nunes, J.H.B.; Hager, S.; Mathuber, M.; May, N.V.; Berger, W.; Keppler, B.K.; Kowol, C.R.; Enyedy, É.A.;
et al. Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance. Cancers 2022, 14, 4455.
https://doi.org/10.3390/cancers14184455
AMA Style
Pósa V, Stefanelli A, Nunes JHB, Hager S, Mathuber M, May NV, Berger W, Keppler BK, Kowol CR, Enyedy ÉA,
et al. Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance. Cancers. 2022; 14(18):4455.
https://doi.org/10.3390/cancers14184455
Chicago/Turabian Style
Pósa, Vivien, Alessia Stefanelli, Julia H. Bormio Nunes, Sonja Hager, Marlene Mathuber, Nóra V. May, Walter Berger, Bernhard K. Keppler, Christian R. Kowol, Éva A. Enyedy,
and et al. 2022. "Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance" Cancers 14, no. 18: 4455.
https://doi.org/10.3390/cancers14184455
APA Style
Pósa, V., Stefanelli, A., Nunes, J. H. B., Hager, S., Mathuber, M., May, N. V., Berger, W., Keppler, B. K., Kowol, C. R., Enyedy, É. A., & Heffeter, P.
(2022). Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance. Cancers, 14(18), 4455.
https://doi.org/10.3390/cancers14184455